These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Author: Nishimiya H, Kosaka Y, Yamashita K, Minatani N, Kikuchi M, Ema A, Nakamura K, Waraya M, Sengoku N, Tanino H, Kuranami M, Watanabe M.
    Journal: Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472.
    Abstract:
    BACKGROUND/AIM: In order to define accurate survival outcome in breast cancer, 10-year follow-up is required and such long-term survival information are few and difficult to gather. PATIENTS AND METHODS: We recruited 253 breast cancer patients who undertook operation with no prior chemotherapy. Ten-year survival outcomes were evaluated by clinicopathological factors. RESULTS: Significant univariate prognostic factors were: T factor, N factor, preoperative values of tumor markers, and biological factors. T-factor, CEA, hormone receptor, and Ki-67 were the final independent prognostic factors of recurrence-free survival through multivariate analysis. The Luminal A group except for the Ki-67-positive cases showed the best survival outcomes, while the HER2-positive or triple-negative (TN) groups showed worse prognosis than the Luminal A group, and Ki-67 was shown to be an excellent prognostic factor in each stage (p<0.01). CONCLUSION: Ki-67 has a great potential as a prognostic biomarker while prognostic information of this sort could be beneficial for development of novel therapeutic strategies.
    [Abstract] [Full Text] [Related] [New Search]